Prostate cancer is a very high incidence of malignant tumors in men worldwide.
The incidence of prostate cancer in China is also increasing year by year.
It is estimated that by 2030, the number of new patients will reach 237,000
.
Accurate diagnosis of prostate cancer can help improve patient care and prognosis
.
Prostate-specific membrane antigen (PSMA) is a transmembrane protein, and its expression level in prostate cancer is closely related to the malignancy of the disease and the survival of patients.
It is a highly sensitive and specific metastatic lesion of prostate cancer.
Ideal biomarker for localized imaging and late-stage radionuclide-targeted therapy
.
According to incomplete statistics, there are hundreds of research drugs targeting PSMA, 5 of which have been approved for marketing.
Since PSMA shows great potential, many multinational pharmaceutical companies, including Novartis and Amgen, are actively deploying research and development.
, Innovative therapies targeting PSMA include radioligand therapy (RLT), ADC, double antibody, CAR-T,
etc.
In China, there are also pharmaceutical companies targeting this drug field for layout
.
On September 2, Yunnan Baiyao announced that the company signed a "Technology Transfer and Cooperative Development Agreement" with Peking University Hospital and Bei Tuo Research Institute, and planned to obtain 20 million yuan for the prostate-specific membrane antigen (PSMA) targeting nucleus jointly developed by the latter.
Drug-related patents, the company will conduct research and development, production and commercialization activities for the cooperation target on a global scale
.
All parties intend to continue the joint research and development of the project on the basis of the current research and development, and finally realize the registration and commercialization of related drugs
.
According to the announcement, the cooperation target has the characteristics of high specificity and low accumulation in non-target organs, which is more conducive to the diagnosis and treatment of in situ and limited-stage prostate cancer
.
At present, the cooperation target has carried out clinical trials in Peking University Hospital, Peking University Cancer Hospital and other hospitals, and its safety and effectiveness have been effectively verified within a certain range
.
In addition to this project, Peking University Hospital agreed to cooperate with Yunnan Baiyao in other tumor fields to develop nuclear medicine diagnosis and treatment products
.
If Peking University Hospital intends to cooperate with a third party to develop, produce or commercialize other tumor nuclear drug products, Yunnan Baiyao has the priority to cooperate in the development, production or commercialization of such products
.
Yunnan Baiyao said that at present, the cooperation target has obtained some research results in the preclinical research stage, showed good results in the clinical trial (IIT) initiated by the researchers, and has obtained relevant patent authorization
.
After completing the transfer and introduction of the cooperation target, the company's central research institute will start relevant research work in accordance with the new drug clinical trial application (IND) application requirements.
The development of this project will help Yunnan Baiyao to accelerate the pace of entering the field of nuclear medicine
.
According to the data, Yunnan Baiyao is a company mainly engaged in chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, and biological products
.
The company will focus on the 1+4+1 strategy to do a good job in corporate transformation and development
.
Among them, "1" refers to the field of deep cultivation of traditional Chinese medicine, "4" refers to the four areas that the company focuses on developing, including the field of oral cavity, skin, orthopedics and women's care, and the other "1" refers to digital technology
.
The 2022 semi-annual report shows that in the first half of the year, the company achieved revenue of 18.
017 billion yuan, a year-on-year decrease of 5.
59%; net profit was 1.
5 billion yuan, a year-on-year decrease of 16.
72%
.
The decline in revenue was mainly caused by the commercial sector being affected by policy factors such as price reductions in centralized pharmaceutical procurement
.
